Article Text

Download PDFPDF
ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis
  1. Maxime Dougados1,
  2. Simon Paternotte1,
  3. Juergen Braun2,
  4. Ruben Burgos-Vargas3,
  5. Walter P Maksymowych4,
  6. Joachim Sieper5,
  7. Désirée van der Heijde6
  1. 1Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
  2. 2Rheumazentrum Ruhrgebeit, Herne, Germany
  3. 3Rheumatology Unit, Hospital General de Mexico, Mexico City, Mexico
  4. 4Medicine/Rheumatic Disease Unit, University of Alberta, Edmonton, Alberta, Canada
  5. 5Medicine/Rheumatology Department, Charite Campus Benjamin Franklin, Berlin, Germany
  6. 6Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Professor Maxime Dougados, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris 75014, France; m.doug{at}


The amount of NSAID intake could be considered as a clinically relevant outcome measure in ankylosing spondylitis. The information should include at least the following: (1) the type of NSAID; (2) the dose; (3) the number of days taking NSAID during the period of interest. The objectives of this initiative were to propose both an NSAID equivalent score and a way of collecting and analysing this information in longitudinal clinical studies/trials. For the NSAID equivalent scoring system, the recommendations are (1) to refer to a scale in which 0 = no intake, 100 = 150 mg diclofenac, 1000 mg naproxen, 200 mg aceclofenac, 400 mg celecoxib, 600 mg etodolac, 90 mg etoricoxib, 200 mg flurbiprofen, 2400 mg ibuprofen, 150 mg indometacin, 200 mg ketoprofen, 15 mg meloxicam, 400 mg phenylbutazone, 20 mg piroxicam, 20 mg tenoxicam; (2) to present the results as mean daily intake by considering the number of days on which NSAID has been taken during a period of interest. This initiative should facilitate the conduct and analysis of clinical studies/trials.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.